Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a suspected or documented complicated urinary tract infection~* Female patients must test negative for pregnancy and agree to use adequate birth control measures~* Nursing women must agree to defer breastfeeding until 5 days after completion of all study antibiotic therapy~Exclusion Criteria:~* Patients with complete obstruction of any portion of the urinary tract~* Patients with rapidly progressive or terminal illness~* Renal transplant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ertapenem sodium (MK0826) (Type: EXPERIMENTAL): ertapenem sodium
- ceftriaxone sodium (Type: ACTIVE_COMPARATOR): ceftriaxone sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).